Echo IQ's breakthrough research on cardiovascular health continues with unveiling of AI-driven aortic stenosis and mitral regurgitation detection results at ESC 2023 Congress

Amsterdam, August 21, 2023 — Echo IQ, a pioneering force in structural heart disease research and artificial intelligence (AI) technology, is set to make waves once again at the European Society of Cardiology's (ESC) 2023 congress in Amsterdam. The company is scheduled to present two exclusive Late-Breaking Science sessions that promise to redefine the landscape of cardiovascular care. Renowned for its commitment to innovative advancements, Echo IQ is poised to unveil groundbreaking insights into the prognosis of mitral regurgitation and revolutionary findings in aortic stenosis detection through AI.

The first session, "MR-NEDA – Prognosis of mild to severe MR," is scheduled for Aug. 25 from 2:00 to 3:15 in the Vilnius room. Distinguished expert Dr David Playford will lead this enlightening discussion, delving into the prognosis of uncorrected severe mitral regurgitation (MR) and offering unprecedented insights into the MR's prognosis across varying severity levels.

On Aug. 27, Echo IQ will present the second session, "DASE-AI: Detect Aortic Stenosis by Echo with Artificial Intelligence." Taking place from 2:00 to 3:20 in the Bratislava room, this Late-Breaking Science session will be spearheaded by Professor Geoff Strange. The research revolves around a clinical cohort study involving an AI-driven automated alert system (AI-AAS) specifically designed to identify severe aortic stenosis. The system's innovation lies in its ability to meticulously scrutinize routine echocardiographic reports and apply its novel AI, based on the world’s largest database of echocardiograms linked to mortality, the National Echo Database of Australia (NEDA), resulting in an unprecedented level of accuracy in detecting the risk of severe aortic stenosis.

"Our commitment to innovative healthcare solutions is epitomized by our participation in the ESC 2023 congress," said Don Fowler, US President at Echo IQ. "The 'DASE-AI' session exemplifies our dedication to harnessing the power of artificial intelligence to revolutionize disease detection, making a profound impact on patient care. As a decision-support tool, we believe the ease by which the cardiac care team can confidently and consistently assess even the most complex cases will greatly uplift the entire Quadruple Aim."

Echo IQ's research journey has pushed boundaries forward, leveraging advanced technology and rigorous analysis to pave the way for unprecedented medical breakthroughs. By combining sophisticated AI technology with comprehensive data analysis, Echo IQ is poised to reshape the future of cardiology and enhance patient outcomes.

For more information on the groundbreaking "DASE-AI: Detect Aortic Stenosis by Echo with Artificial Intelligence" session and Echo IQ's commitment to innovative research, visit echoiq.ai/esc or reach out for further media interest to Elizabeth Jennings at Elizabeth.jennings@echoiq.ai.